8-K
filed May 16, 2022, 7:59 PM ET
ticker ZNTL
CIK 0001725160
leadership
confidence high
sentiment neutral
materiality 0.75
Zentalis CEO Anthony Sun resigns; Kimberly Blackwell appointed as CEO effective May 16
Zentalis Pharmaceuticals, Inc.
- Anthony Y. Sun resigned as President, CEO and Chairman effective May 10; Kevin Bunker appointed interim PEO.
- Kimberly Blackwell appointed President and CEO effective ~May 16; David Johnson named Chairman.
- Blackwell receives $680k base salary, 60% target bonus, $250k sign-on bonus (pro-rated clawback within 1 year).
- Equity grants: option for 3.0% of outstanding shares (4-yr vest) and 0.75% (vests on FDA approval of a product or change in control).
- Sun receives severance: 18 months base salary plus prorated 2022 target bonus, continued vesting of equity up to Feb 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kimberly Blackwell was appointed as President and Chief Executive Officer at Zentalis Pharmaceuticals, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
the Board appointed Kimberly Blackwell, M.D., a current member of the Board, as President and Chief Executive Officer of the Company, and designated Dr. Blackwell as the Company’s principal executive officer, in each case effective as of the commencement of Dr. Blackwell’s employment with the Company, which is expected to be on or about May 16, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin M. Bunker was appointed as Principal Executive Officer (Interim) at Zentalis Pharmaceuticals, Inc..
- Action
- designated as interim principal executive officer
- Role
- Principal Executive Officer (Interim)
Exact text from the filing
the Board designated Kevin M. Bunker, Ph.D., the Company’s Chief Operating Officer, as the Company’s principal executive officer on an interim basis
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David M. Johnson was appointed as Chairman of the Board at Zentalis Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
appointed David M. Johnson as Chairman of the Board, in each case effective as of the Resignation Effective Time
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anthony Y. Sun resigned as Chairman of the Board at Zentalis Pharmaceuticals, Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
On May 10, 2022, Anthony Y. Sun, M.D., notified Zentalis Pharmaceuticals, Inc. (the “Company”) of his resignation as President and Chief Executive Officer of the Company and as a director and Chairman of the Board of Directors of the Company (the “Board”), effective as of 11:59 p.m. on May 10, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anthony Y. Sun resigned as President and Chief Executive Officer at Zentalis Pharmaceuticals, Inc..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
On May 10, 2022, Anthony Y. Sun, M.D., notified Zentalis Pharmaceuticals, Inc. (the “Company”) of his resignation as President and Chief Executive Officer of the Company and as a director and Chairman of the Board of Directors of the Company (the “Board”), effective as of 11:59 p.m. on May 10, 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.